Ameriprise’s Kezar Life Sciences KZR Stock Holding History

Ameriprise’s Portfolio KZR Stock Details KZR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,276	Closed	-$55.8K	–	3925
2023 Q2	$55.8K	Buy	+2,276	New	+$59.3K	﹤0.01%	3859
2023 Q1	–	Sell	-1,873	Closed	-$132K	–	3995
2022 Q4	$132K	Buy	+1,873	New	+$139K	﹤0.01%	3774

Other funds holding KZR

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ameriprise's KZR Position: Q3 2023 in Review

Ameriprise sold out of Kezar Life Sciences (KZR) in Q3 2023, closing a stake of 2,276 shares — an estimated $55.8K sold.

Ameriprise first reported a position in KZR in Q4 2022 and held it in 2 quarters. The position peaked at $132K in Q4 2022. 82 funds tracked by Wall St. Rank hold KZR as of Q3 2023.

Ameriprise reported no remaining Kezar Life Sciences position as of Q3 2023 after selling out during the quarter.
Ameriprise sold 2,276 Kezar Life Sciences shares in Q3 2023, an estimated $55.8K.
Ameriprise first reported a position in Kezar Life Sciences in Q4 2022 and held it in 2 quarters.
Ameriprise's Kezar Life Sciences position peaked at $132K in Q4 2022.
82 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q3 2023.

Based on Ameriprise's 13F filing for Q3 2023, filed 14 Nov 2023.